Department of General Surgery, Linping Campus, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 311100, China.
J Environ Pathol Toxicol Oncol. 2024;43(1):79-90. doi: 10.1615/JEnvironPatholToxicolOncol.2023048594.
Present studies report that high expression of GINS complex subunit 1 (GINS1) is notably pertinent to poor survival for hepatocellular carcinoma (HCC), but it remains unclear how GINS1 affects the progression of HCC. This study aims at investigating the mechanism by which GINS1 affects HCC cell proliferation and stemness. We performed bioinformatics analysis for determining GINS1 expression in HCC tissues, as well as the HCC patients' survival rate with different expression levels of GINS1. E2F transcription factor 1 (E2F1) was predicted as the upstream transcription factor of GINS1, and the binding relation between the two was verified by chromatin immunoprecipitation and dual-luciferase reporter assays. Quantitative real-time polymerase chain reaction was adopted to evaluate the expression of GINS1 and E2F1. The protein expression levels of GINS1, E2F1, and cell stemness-related genes (SOX-2, NANOG, OCT4, and CD133) were detected by Western blot. Afterward, the proliferative capacity and stemness of HCC tumor cells were determined through colony formation, cell counting kit-8, and sphere formation assays. Our study found the high expression of GINS1 and E2F1 in HCC, and overexpressed GINS1 markedly enhanced the sphere formation and proliferation of HCC cells, while silencing GINS1 led to the opposite results. Besides, E2F1 promoted the transcription of GINS1 by working as an upstream transcription factor. The results of the rescue experiment suggested that overexpressed E2F1 could offset the suppressive effect of GINS1 silencing on HCC cell stemness and proliferation. We demonstrated that the transcription factor E2F1 accelerated cell proliferation and stemness in HCC by activating GINS1 transcription. The results can provide new insight into the GINS1-related regulatory mechanism in HCC, which suggest that it may be an effective way for HCC treatment by targeting the E2F1/GINS1 axis.
目前的研究报告表明,GINS 复合物亚基 1(GINS1)的高表达与肝细胞癌(HCC)的不良预后显著相关,但 GINS1 如何影响 HCC 的进展尚不清楚。本研究旨在探讨 GINS1 影响 HCC 细胞增殖和干性的机制。我们进行了生物信息学分析,以确定 HCC 组织中 GINS1 的表达情况,以及 GINS1 表达水平不同的 HCC 患者的生存率。E2F 转录因子 1(E2F1)被预测为 GINS1 的上游转录因子,通过染色质免疫沉淀和双荧光素酶报告基因检测验证了两者之间的结合关系。采用定量实时聚合酶链反应评估 GINS1 和 E2F1 的表达。通过 Western blot 检测 GINS1、E2F1 和细胞干性相关基因(SOX-2、NANOG、OCT4 和 CD133)的蛋白表达水平。随后,通过集落形成、细胞计数试剂盒-8 和球体形成测定来确定 HCC 肿瘤细胞的增殖能力和干性。我们的研究发现 GINS1 和 E2F1 在 HCC 中高表达,过表达 GINS1 显著增强了 HCC 细胞的球体形成和增殖能力,而沉默 GINS1 则导致相反的结果。此外,E2F1 通过作为上游转录因子促进 GINS1 的转录。挽救实验的结果表明,过表达的 E2F1 可以抵消 GINS1 沉默对 HCC 细胞干性和增殖的抑制作用。我们证明转录因子 E2F1 通过激活 GINS1 转录来加速 HCC 中的细胞增殖和干性。这些结果为 HCC 中 GINS1 相关调控机制提供了新的见解,表明通过靶向 E2F1/GINS1 轴可能是治疗 HCC 的有效方法。